RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:36355

Bleeding disorder due to P2Y12 defect

low confidenceDisorder

Also known as: Bleeding disorder due to ADP platelet receptor P2Y12 defect

Publications

5,746

Trials

0

Interventional, condition-specific

Researchers

32

Distinct authors in sample

Gene link

P2RY12

Definitive

Readiness

4/6

Stages with a signal

Clinical definition (Orphanet)

P2Y12 defect is a rare hemorrhagic disorder characterized by mild to moderate bleeding diathesis with easy bruising, mucosal bleedings, and excessive post-operative hemorrhage due to defect of the platelet P2Y12 receptor resulting in selective impairment of platelet responses to adenosine diphosphate.

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (1)

platelet-type bleeding disorder 8

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

4/6 stages with a signal

No matched interventional trial, but a gene association and an animal model are on record — often described as translation-ready / stalled at the clinical step.

  1. Gene identifiedPresent

    Definitive — P2RY12

  2. LiteraturePresent

    5,746 matched papers (4,601 in last 10 years) Source

  3. Phenotype characterisedPresent

    7 HPO annotations (e.g. Prolonged bleeding after surgery; Impaired ADP-induced platelet aggregation; Abnormal bleeding) Source

  4. Animal modelPresent

    2 genotype models (Mus musculus) Source

  5. Orphan designationNot found

    No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source

  6. Interventional trialNot found

    No matched interventional trial under our ClinicalTrials.gov rules

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (P2RY12).

GenCC classification: Definitive.

Phenotypes (Monarch / HPO)

7

Associated phenotypes · MONDO:0012354

  • Prolonged bleeding after surgery
  • Impaired ADP-induced platelet aggregation
  • Abnormal bleeding
  • Ecchymosis
  • Bruising susceptibility

Showing 5 of 7 — open Monarch for the full list.

Animal models (Monarch / Alliance)

2

Model associations linked to this Mondo ID

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.

Open Targets candidates

No drugs or clinical candidates returned for this Mondo ID on Open Targets.

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

5,746

5,746 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

5,746 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

4,601 in the last 10 years · low confidence

Phrase hits: 2 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

32

Distinct author names in 2 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Adel S1 paper · 2015

    Institute of Biochemistry, Charité - University Medicine Berlin, Charitéplatz 1, CCO-Building, Virchowweg 6, D-10117 Berlin, Germany.

    Papers in Europe PMC
  2. 02
    Bury L1 paper · 2024

    Department of Medicine, Section of Internal and Cardiovascular Medicine, University of Perugia, Perugia, Italy.

    Papers in Europe PMC
  3. 03
    Cattaneo M1 paper · 2024

    Dipartimento di Scienze della Salute, Università degli Studi di Milano, Milan, Italy.

    Papers in Europe PMC
  4. 04
    Cooper N1 paper · 2024

    Centre for Haematology, Imperial College London, London, UK.

    Papers in Europe PMC
  5. 05
    Downes K1 paper · 2024

    Department of Haematology, University of Cambridge, Cambridge, UK.

    Papers in Europe PMC
  6. 06
    Frantz A1 paper · 2024

    Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

    Papers in Europe PMC
  7. 07
    Freson K1 paper · 2024

    Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium. Electronic address: kathleen.freson@kuleuven.be.

    Papers in Europe PMC
  8. 08
    Futchi I1 paper · 2024

    Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

    Papers in Europe PMC
  9. 09
    Gresele P1 paper · 2024

    Department of Medicine, Section of Internal and Cardiovascular Medicine, University of Perugia, Perugia, Italy.

    Papers in Europe PMC
  10. 10
    Heydeck D1 paper · 2015

    Institute of Biochemistry, Charité - University Medicine Berlin, Charitéplatz 1, CCO-Building, Virchowweg 6, D-10117 Berlin, Germany.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).

Data as of 11 September 2026 · last trial check 11 September 2026

No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.

low confidence · 38.6th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-29

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Bleeding disorder due to P2Y12 defect — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

("Bleeding disorder due to P2Y12 defect" OR "Bleeding disorder due to ADP platelet receptor P2Y12 defect" OR "platelet-type bleeding disorder 8") OR ("P2RY12" OR "P2RY12 syndrome" OR "P2RY12-related")

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Bleeding disorder due to P2Y12 defect" OR "Bleeding disorder due to ADP platelet receptor P2Y12 defect" OR "platelet-type bleeding disorder 8"

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (5746) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity

Ingested 2026-07-26T23:53:15.890Z